PRDS—…it's a hedge, but also a means of forcing myself to better track ENTA competition.
There are a few other companies who are trying to improve on PFE’s Paxlovid. For ENTA longs, buying PRDS as a hedge seems reasonable, but I’m disinclined to pay more than the $10 the institutional shareholders paid in the recent $75M raise, so I’m staying on the sidelines for now.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.